fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

NBSE

Neubase Therapeutics

  ( )

Page Views : 83172

vista's key points

  • Neubase is led by Chairman & CEO, Founder Dietrich A. Stephan, Ph.D. an industry veteran having had a career in academia and in industry. Stephan served as Deputy Director for Discovery Research and chair of the neurogenomics division at TGen, and served as professor and chairman of the Department of Human Genetics at the University of Pittsburgh/UPMC.
  • NeuBase is advancing an entirely new class of medicines to address many currently undruggable diseases.
  • NeuBase's ultra-precision genetic medicines have demonstrated in proof-of-concept preclinical studies treatment tolerability, selective engagement of different disease-driving mutations at the DNA or RNA level, and broad tissue distribution after systemic administration.
  • NeuBase has validated their ability to Drug the Genome™ to address both rare and common diseases without the limitations of early precision genetic medicine technologies.
  • NueBase’s delivery shuttle enables pharmacology across programs in multiple tissues, including in the brain and muscle, after subcutaneous administration.
  • As of September 30, 2021, the Company had cash and cash equivalents of approximately $52.9 million, compared with approximately $32.0 million as of September 30, 2020. NeuBase estimates its current cash and cash equivalents are sufficient to fund currently planned operating and capital expenditures into the first quarter of CY2023.

vista's key points

  • Neubase is led by Chairman & CEO, Founder Dietrich A. Stephan, Ph.D. an industry veteran having had a career in academia and in industry. Stephan served as Deputy Director for Discovery Research and chair of the neurogenomics division at TGen, and served as professor and chairman of the Department of Human Genetics at the University of Pittsburgh/UPMC.
  • NeuBase is advancing an entirely new class of medicines to address many currently undruggable diseases.
  • NeuBase's ultra-precision genetic medicines have demonstrated in proof-of-concept preclinical studies treatment tolerability, selective engagement of different disease-driving mutations at the DNA or RNA level, and broad tissue distribution after systemic administration.
  • NeuBase has validated their ability to Drug the Genome™ to address both rare and common diseases without the limitations of early precision genetic medicine technologies.
  • NueBase’s delivery shuttle enables pharmacology across programs in multiple tissues, including in the brain and muscle, after subcutaneous administration.
  • As of September 30, 2021, the Company had cash and cash equivalents of approximately $52.9 million, compared with approximately $32.0 million as of September 30, 2020. NeuBase estimates its current cash and cash equivalents are sufficient to fund currently planned operating and capital expenditures into the first quarter of CY2023.

company profile

 

vista's view

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) is a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines. As Founder, Chief Executive Officer, and Chairman of NeuBase, Dietrich A. Stephan, Ph.D., stated recently,  “NeuBase is focused on significantly reducing the burden...

Read More

exclusive content

 

Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates